Match antiemetics to the source of nausea, build effective prevention, and recognize cardiac, motor, anticholinergic, and drug interaction risks.
Ondansetron can prevent vomiting after chemotherapy yet disappoint someone on a rolling boat. The symptom is the same; the input to the vomiting network is different. Choose a drug by the cause, the need for prevention or rescue, and the patient's vulnerability to its adverse effects.
Find where the nausea starts
A vomiting episode is the output of an integrated brainstem network, not a diagnosis. Gastrointestinal irritation, circulating drugs, vestibular mismatch, and higher brain inputs can all contribute. Persistent vomiting with abdominal distension, severe headache, focal neurologic findings, metabolic disturbance, or dehydration calls for assessment of the cause alongside symptom control. A successful antiemetic does not establish that the underlying illness is harmless.
Receptor geography. Each entry describes an input and its useful pharmacologic target.
Gut to brainstem
Enterochromaffin serotonin stimulates vagal 5-HT3 receptors. Ondansetron, granisetron, and palonosetron reduce this signal.
Blood to area postrema
The area postrema samples circulating emetogens. Central D2 and 5-HT3 antagonism can reduce chemical triggering.
Vestibular nuclei
Sensory mismatch recruits central H1 and muscarinic pathways. Meclizine, dimenhydrinate, and scopolamine fit this input.
Central integration
Substance P acts at NK1 receptors. Aprepitant adds complementary chemotherapy coverage. Cannabinoids modulate central pathways with substantial cognitive effects.
These are overlapping circuits, not isolated compartments. A receptor map predicts useful choices without claiming that one transmitter causes every episode. [1][2][4][5]
5-HT3 antagonists act centrally as well as peripherally. Their failure in motion sickness does not mean they cannot enter or affect the brain. It means they do not adequately target the central vestibular pathway responsible for that problem. [5]
Prevent chemotherapy symptoms across the treatment window
Acute chemotherapy-induced nausea and vomiting occurs within the first 24 hours. Delayed symptoms occur afterward, commonly assessed through 120 hours. Serotonin is particularly important early and substance P contributes strongly to delayed symptoms, but the mechanisms overlap. NK1 antagonists are useful in both phases. They should not be withheld until the second day simply because the lesson associates them with delayed emesis.
For adults receiving highly emetogenic intravenous chemotherapy such as single-day cisplatin, current MASCC/ESMO guidance recommends a four-drug preventive regimen consisting of a 5-HT3 antagonist, an NK1 antagonist, dexamethasone, and olanzapine. Anthracycline plus cyclophosphamide regimens in breast cancer also warrant four-drug prophylaxis. Fosaprepitant is an intravenous NK1 option in these regimens. This is prevention before treatment, with subsequent doses determined by the chemotherapy and the specific antiemetic regimen. It is not a recommendation to give every drug indefinitely. [1]
Olanzapine affects several neurotransmitter receptors and contributes meaningfully to nausea control, which can remain poor even when vomiting is suppressed. Sedation matters, especially in older adults or people taking opioids. A lower starting dose or bedtime administration may be appropriate when sedation is a concern. Dexamethasone adds efficacy through a different pharmacologic strategy; its exact antiemetic mechanism is not completely established. Repeated courses require attention to glucose, sleep, infection risk, and the oncology protocol.
Breakthrough symptoms require a review of adherence, the preventive regimen, constipation, concurrent medications, electrolyte abnormalities, and alternative causes. When olanzapine was not already used, it is an evidence-supported rescue option. Do not reflexively repeat ondansetron at increasingly large doses. Treatment should add a useful mechanism and address the reason prevention failed. Dronabinol and nabilone are selected cannabinoids reserved for symptoms inadequately controlled by conventional therapy. Psychiatric, cognitive, and hemodynamic effects limit their usefulness. Nabilone is given according to its prescribed chemotherapy schedule, not as an unsupervised as-needed drug; its label advises against driving or hazardous work during treatment. [10][1][6]
For intravenous anticancer treatment, low emetic risk may need only one preventive agent. Minimal emetic risk generally does not need routine prophylaxis in someone without a prior history of treatment-related nausea or vomiting. More drugs are not automatically better when the baseline risk is low. [1]
Three settings that change the usual prescription
Motion exposure
Meclizine and dimenhydrinate are centrally active first-generation H1 antihistamines. Promethazine is another centrally active motion-sickness option and is particularly sedating. Scopolamine is an antimuscarinic used preventively. They work best when available before the provoking exposure. A transdermal patch has a delayed onset and should not be treated as an immediate rescue drug once a person is repeatedly vomiting. Looking toward the horizon and reducing conflicting visual input may help. Newer minimally sedating antihistamines, such as loratadine, are poor substitutes because they do not adequately act at the relevant central receptors. [5]
Gastroparesis
Metoclopramide combines central D2 blockade with enhanced upper gastrointestinal motility. Its prokinetic activity supports coordinated gastric emptying, including through serotonergic and cholinergic mechanisms. That makes it useful in selected adults with diabetic gastroparesis. Ondansetron can reduce nausea but does not restore gastric emptying. Confirm delayed emptying and exclude mechanical obstruction rather than diagnosing gastroparesis from vomiting alone. Stimulation of motility is unsafe when gastrointestinal obstruction, perforation, or hemorrhage makes increased contractions hazardous. [3]
Surgery and pregnancy
Postoperative prevention is matched to risk and usually combines mechanisms when risk is substantial. Transdermal scopolamine is one preventive option, but its anticholinergic effects may make it unsuitable for someone with urinary retention, angle-closure glaucoma, or cognitive vulnerability. Correct electrolyte depletion rather than merely selecting a different antiemetic. In pregnancy, assess severity, hydration, weight loss, and alternative causes. Pyridoxine, alone or with doxylamine, is an established initial drug approach. Persistent symptoms need individualized obstetric management rather than automatic substitution of a chemotherapy regimen. [2][5][7][8]
Read the adverse effect back to the mechanism
Dopamine blockade
Metoclopramide and prochlorperazine can cause extrapyramidal symptoms. Acute dystonia produces sustained painful contractions, often involving the neck, jaw, or eyes. Akathisia produces inner restlessness. Parkinsonism produces rigidity and slowed activity. Tardive dyskinesia may produce repetitive oral or limb motions after cumulative exposure and can persist after stopping treatment. These syndromes are not interchangeable. Suspected tardive dyskinesia requires immediate metoclopramide discontinuation and evaluation.
Dopamine normally inhibits prolactin secretion. Blocking that signal can cause galactorrhea, menstrual disturbance, or sexual symptoms. Metoclopramide should be avoided in Parkinson disease and with additive dopamine-blocking drugs when possible. A prior metoclopramide dystonic reaction or tardive dyskinesia is a contraindication. [3]
5-HT3 blockade
Ondansetron commonly causes headache or constipation and can prolong QT. Congenital long QT syndrome warrants avoidance. Hypokalemia, hypomagnesemia, bradyarrhythmias, heart failure, and other QT-prolonging medicines warrant correction of reversible risks and appropriate ECG monitoring. QT effects are not identical across every drug in the class, so assess the actual product rather than assigning an identical risk to all 5-HT3 antagonists.
Labels report serotonin syndrome, particularly with concomitant serotonergic drugs. Agitation, hyperreflexia, clonus, fever, and autonomic instability should trigger recognition and treatment of a toxicity syndrome; nausea alone does not establish it. Concomitant apomorphine is contraindicated because profound hypotension and loss of consciousness have occurred. [2]
Droperidol also has clinically important QT risk. Its US label calls for a pretreatment ECG and continued monitoring for 2 to 3 hours after treatment; known or suspected QT prolongation is a contraindication. Substituting it for ondansetron does not solve a long-QT problem. [9]
Central H1, muscarinic, and cannabinoid effects
Sedation can impair driving even when nausea improves. Antimuscarinic effects add dry mouth, impaired near vision, constipation, urinary retention, and confusion. Painful red eye with halos suggests acute angle closure, not routine mild blurred vision. Scopolamine can also reduce sweating and cause serious hyperthermia, especially with environmental heat; the 2025 label warning makes hot-weather counseling particularly relevant. Nabilone can cause dysphoria, panic, perceptual changes, dizziness, and postural hypotension. Alcohol, opioids, benzodiazepines, and other sedatives can intensify impairment. [5][6][8]
Attach a monitoring plan to the drug
Aprepitant is a CYP3A4 substrate and has inhibitory and inducing effects that depend on regimen and timing. Its interactions cannot be reduced to a single prediction that every coadministered drug concentration rises. Pimozide is contraindicated because increased exposure can cause dangerous cardiac effects. Dexamethasone doses are reduced in specified aprepitant regimens to account for increased steroid exposure; follow the actual combination protocol. [4]
Warfarin. Aprepitant can lower INR. Monitor during the two weeks after initiation, particularly days 7 to 10, rather than automatically changing the warfarin dose.
Hormonal contraception. Use effective alternative or backup nonhormonal contraception during treatment and for one month after the last aprepitant dose. The pharmacokinetic warning mentions 28 days; the counseling instruction is one month.
Metoclopramide duration. Use the shortest effective course. The February 2026 Reglan label limits documented refractory GERD treatment to 12 weeks. For diabetic gastroparesis, avoid total treatment beyond 12 weeks; if longer use is unavoidable, routinely monitor for tardive dyskinesia. Twelve weeks is not a risk-free allowance. Renal impairment may require dose reduction. [3][4]
Name the cause, choose prevention or rescue, match the receptor, then check cardiac risk, motor history, bowel obstruction, cognition, and interactions. Reassess persistent symptoms instead of stacking drugs without a new explanation.
Apply the receptor choice
Case 1
Show answer and explanations for case 1
A. Meclizine and scopolamine for combined vestibular nausea prevention (Why this does not fit)
These predominantly target vestibular nausea rather than the chemotherapy pathways in this patient.
B. Nabilone alone (Why this does not fit)
Nabilone is a selected option after inadequate conventional control, not routine first-cycle monotherapy.
C. 5-HT3 and NK1 antagonists, dexamethasone, and olanzapine (Best answer)
Four complementary drugs provide guideline-based prevention for highly emetogenic chemotherapy.
D. Ondansetron alone (Why this does not fit)
Single-agent serotonin blockade is inadequate routine prophylaxis for cisplatin's high emetic risk.
Takeaway: High emetic risk calls for planned multidrug prevention.
